Basilea Pharmaceutica AG (SWX:BSLN)
Switzerland · Delayed Price · Currency is CHF 51.90
-0.30 (-0.57%)
Jul 31, 2026, 5:30 PM CET
Basilea Pharmaceutica AG Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 232.38 | 208.54 | 157.63 | 147.77 | 148.12 | |
Revenue Growth | 11.43% | 32.30% | 6.68% | -0.24% | 16.06% |
Cost of Revenue | 39.32 | 38.68 | 26.79 | 24.6 | 24.07 |
Gross Profit | 193.06 | 169.86 | 130.84 | 123.16 | 124.05 |
Selling, General & Admin | 35.62 | 31.54 | 33.78 | 30.82 | 29.72 |
Research & Development | 105.9 | 77.14 | 77.85 | 73.8 | 93.16 |
Other Operating Expenses | - | - | - | - | -0.02 |
Total Operating Expenses | 141.51 | 108.69 | 111.64 | 104.62 | 122.86 |
Operating Income | 51.55 | 61.18 | 19.21 | 18.54 | 1.19 |
Interest Income | 1.27 | 1.42 | 1.69 | 0.33 | 0.07 |
Interest Expense | -3.36 | -4.34 | -11.2 | -9.85 | -8.15 |
Other Non-Operating Income (Expense) | -3.58 | 2.01 | 0.77 | 3.08 | 0.1 |
Total Non-Operating Income (Expense) | -5.67 | -0.92 | -8.74 | -6.44 | -7.98 |
Pretax Income | 45.88 | 60.26 | 10.46 | 12.1 | -6.79 |
Provision for Income Taxes | 5.64 | -17.33 | 0.01 | -0.05 | 0.04 |
Net Income | 40.24 | 77.59 | 10.45 | 12.15 | -6.83 |
Net Income to Common | 40.24 | 77.59 | 10.45 | 12.15 | -6.83 |
Net Income Growth | -48.14% | 642.45% | -13.96% | - | - |
Shares Outstanding (Basic) | 12 | 12 | 12 | 12 | 12 |
Shares Outstanding (Diluted) | 14 | 14 | 12 | 12 | 12 |
Shares Change | -1.23% | 14.10% | 1.67% | 2.24% | 13.62% |
EPS (Basic) | 3.29 | 6.42 | 0.87 | 1.02 | -0.58 |
EPS (Diluted) | 3.14 | 5.83 | 0.86 | 1.02 | -0.58 |
EPS Growth | -46.14% | 577.91% | -15.69% | - | - |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 59.47 | 72.65 | 13.43 | 3.92 | -32.6 |
Free Cash Flow Growth | -18.14% | 440.89% | 242.83% | - | - |
Free Cash Flow Per Share | 4.35 | 5.24 | 1.11 | 0.33 | -2.79 |
Gross Margin | 83.08% | 81.45% | 83.00% | 83.35% | 83.75% |
Operating Margin | 22.18% | 29.34% | 12.18% | 12.55% | 0.80% |
Profit Margin | 17.32% | 37.21% | 6.63% | 8.22% | -4.61% |
FCF Margin | 25.59% | 34.84% | 8.52% | 2.65% | -22.01% |
EBITDA | 53.36 | 62.91 | 20.78 | 19.64 | 1.94 |
EBITDA Margin | 22.96% | 30.17% | 13.18% | 13.29% | 1.31% |
EBIT | 51.55 | 61.18 | 19.21 | 18.54 | 1.19 |
EBIT Margin | 22.18% | 29.34% | 12.18% | 12.55% | 0.80% |
Effective Tax Rate | 12.28% | -28.76% | 0.10% | -0.37% | -0.54% |